Clinical presentations of skin of color in oncodermatology - 08/10/24
Doi : 10.1016/j.jaad.2024.08.060
Anna Chen, BA a, ⁎ 
, Leore Lavin, MA a, Alina Markova, MD a, Mario E. Lacouture, MD a, b
, Leore Lavin, MA a, Alina Markova, MD a, Mario E. Lacouture, MD a, b a Department of Medicine, Dermatology, Memorial Sloan Kettering Cancer Center, Service, New York, New York
b Dermatology Division, Department of Medicine, NYU Grossman Long Island School of Medicine, New York, New York
∗Correspondence to: Anna Chen, BA, Department of Medicine, Dermatology, Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY 10021.Department of Medicine, DermatologyMemorial Sloan Kettering Cancer Center, Service1945 Eastchester RdBronxNY10021
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Tuesday 08 October 2024
Key words : adverse event, drug rash, drug reaction, oncodermatology, oncology, skin of color
| Funding sources: NIH/NCI Cancer Center Support Grant P30 CA008748. Dr Markova receives research funding from Amryt Pharma, Incyte Corporation, Kintara Therapeutics, Novartis, Novocure. Dr Lacouture receives research funding from Lutris, Paxman, Novocure, OQL, Novartis, and AZ and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748. |
|
| Patient consent: There are no recognizable/identifiable patient images. |
|
| IRB approval status: MSKCC IRB 16-458. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?